Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone

Bone

Volumn 44, Issue 1, 2009, Pages 160-167

  Virk, Mandeep S ^a   Petrigliano, Frank A ^b   Liu, Nancy Q ^b   Chatziioannou, Arion F ^b   Stout, David ^b   Kang, Christine O ^b   Dougall, William C ^c   Lieberman, Jay R ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

Author keywords

Bone metastasis; Bone morphogenetic protein (BMP); Prostate cancer; Receptor activator of nuclear factor kappa B Fc protein (RANK:Fc protein); Receptor activator of nuclear factor kappa B ligand (RANKL)

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COMPLEMENTARY DNA; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; NOGGIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; CANCER CELL; CYCLOTRON; DISEASE COURSE; HINDLIMB; HUMAN; HUMAN CELL; IMAGING SYSTEM; IMPLANTATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; SCID MOUSE; TIBIA;

ACID PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HINDLIMB; HUMANS; ISOENZYMES; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OSTEOLYSIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TIBIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 57449108869     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.09.009     Document Type: Article

References (48)

1. Virk M.S., and Lieberman J.R. Tumor metastasis to bone. Arthritis Res. Ther. 9 Suppl. 1 (2007) S5
2. Coleman R.E. Management of bone metastases. Oncologist 5 (2000) 463-470
3. Saad F., Clarke N., and Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur. Urol 49 (2006) 429-440
4. Carlin B.I., and Andriole G.L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88 (2000) 2989-2994
5. Yin J.J., Pollock C.B., and Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 15 (2005) 57-62
6. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350 (2004) 1655-1664
7. Yoneda T., and Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 328 (2005) 679-687
8. Keller E.T., Zhang J., Cooper C.R., Smith P.C., McCauley L.K., Pienta K.J., et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 20 (2001) 333-349
9. Boyce B.F., Yoneda T., and Guise T.A. Factors regulating the growth of metastatic cancer in bone. Endocr.-Relat. Cancer 6 (1999) 333-347
10. Cooper C.R., Chay C.H., Gendernalik J.D., Lee H.L., Bhatia J., Taichman R.S., et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97 (2003) 739-747
11. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12 (2006) 6213s-6216s
12. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
13. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
14. Roodman G.D. Regulation of osteoclast differentiation. Ann. N.Y. Acad. Sci. 1068 (2006) 100-109
15. Boyce B.F., Yamashita T., Yao Z., Zhang Q., Li F., and Xing L. Roles for NF-kappaB and c-Fos in osteoclasts. J. Bone Miner. Metab. 23 Suppl (2005) 11-15
16. Lee Y., Schwarz E., Davies M., Jo M., Gates J., Wu J., et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J. Orthop. Res. 21 (2003) 62-72
17. Michigami T., Ihara-Watanabe M., Yamazaki M., and Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 61 (2001) 1637-1644
18. Ohshiba T., Miyaura C., Inada M., and Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer 88 (2003) 1318-1326
19. Feeley B.T., Liu N.Q., Conduah A.H., Krenek L., Roth K., Dougall W.C., et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J. Bone Miner. Res. 21 (2006) 1571-1580
20. Whang P.G., Schwarz E.M., Gamradt S.C., Dougall W.C., and Lieberman J.R. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J. Orthop. Res. 23 (2005) 1475-1483
21. Zhang J., Dai J., Yao Z., Lu Y., Dougall W., and Keller E.T. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 63 (2003) 7883-7890
22. Lieberman J.R., Daluiski A., and Einhorn T.A. The role of growth factors in the repair of bone. biology and clinical applications. J. Bone Joint Surg. Am. 84-A (2002) 1032-1044
23. Chen D., Zhao M., and Mundy G.R. Bone morphogenetic proteins. Growth Factors 22 (2004) 233-241
24. Bobinac D., Maric I., Zoricic S., Spanjol J., Dordevic G., Mustac E., et al. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat. Med. J. 46 (2005) 389-396
25. Deng H., Makizumi R., Ravikumar T.S., Dong H., Yang W., and Yang W.L. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp. Cell Res. 313 (2007) 1033-1044
26. Brubaker K.D., Corey E., Brown L.G., and Vessella R.L. Bone morphogenetic protein signaling in prostate cancer cell lines. J. Cell. Biochem. 91 (2004) 151-160
27. Langenfeld E.M., Calvano S.E., Abou-Nukta F., Lowry S.F., Amenta P., and Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24 (2003) 1445-1454
28. Schwalbe M., Sanger J., Eggers R., Naumann A., Schmidt A., Hoffken K., et al. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int. J. Oncol. 23 (2003) 89-95
29. Yang S., Zhong C., Frenkel B., Reddi A.H., and Roy-Burman P. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res. 65 (2005) 5769-5777
30. Ye L., Lewis-Russell J.M., Kyanaston H.G., and Jiang W.G. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol. Histopathol. 22 (2007) 1129-1147
31. Feeley B.T., Gamradt S.C., Hsu W.K., Liu N., Krenek L., Robbins P., et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J. Bone Miner. Res. 20 (2005) 2189-2199
32. Feeley B.T., Krenek L., Liu N., Hsu W.K., Gamradt S.C., Schwarz E.M., et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38 (2006) 154-166
33. Hsu W.K., Virk M.S., Feeley B.T., Stout D.B., Chatziioannou A.F., and Lieberman J.R. Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model with using 18F-FDG and 18F-Fluoride PET/CT. J. Nucl. Med. 49 3 (2008) 414-421 [2008 Feb 20, Electronic publication ahead of print]
34. Narita N., Kato K., Nakagaki H., Ohno N., Kameyama Y., and Weatherell J.A. Distribution of fluoride concentration in the rat's bone. Calcif. Tissue Int. 46 (1990) 200-204
35. Hawkins R.A., Choi Y., Huang S.C., Hoh C.K., Dahlbom M., Schiepers C., et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J. Nucl. Med. 33 (1992) 633-642
36. Brown J.M., Zhang J., and Keller E.T. Opg, RANKl, and RANK in cancer metastasis: expression and regulation. Cancer Treat. Res. 118 (2004) 149-172
37. Wittrant Y., Theoleyre S., Chipoy C., Padrines M., Blanchard F., Heymann D., et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim. Biophys. Acta 1704 (2004) 49-57
38. Ignatoski K.M., Escara-Wilke J.F., Dai J.L., Lui A., Dougall W., Daignault S., et al. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 68 (2008) 820-829
39. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420 (2002) 636-642
40. Berger F., Lee Y.P., Loening A.M., Chatziioannou A., Freedland S.J., Leahy R., et al. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 1225-1236
41. Myers R., and Hume S. Small animal PET. Eur. Neuropsychopharmacol. 12 (2002) 545-555
42. Herschman H.R. Micro-PET imaging and small animal models of disease. Curr. Opin. Immunol. 15 (2003) 378-384
43. Vessella R.L., and Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res. 12 (2006) 6285s-6290s
44. Lipton A. Future treatment of bone metastases. Clin. Cancer Res. 12 (2006) 6305s-6308s
45. Storey J.A., and Torti F.M. Bone metastases in prostate cancer: a targeted approach. Curr. Opin. Oncol. 19 (2007) 254-258
46. Bagi C.M. Targeting of therapeutic agents to bone to treat metastatic cancer. Adv. Drug Deliv. Rev. 57 (2005) 995-1010
47. Duivenvoorden W.C., Vukmirovic-Popovic S., Kalina M., Seidlitz E., and Singh G. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br. J. Cancer 96 (2007) 1526-1531
48. Banerjee S., Hussain M., Wang Z., Saliganan A., Che M., Bonfil D., et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 67 (2007) 3818-3826